Pacira BioSciences faces significant risk as generic challenges threaten Exparel, its flagship product responsible for 78% of 2024 revenue. PCRX's complex formulation, robust patent estate, and ...

Jamie Dimon is right to be alarmed about our national-security vulnerabilities, especially an overreliance on China and India for generic prescription drugs (“Investments for National Security,” op-ed ...

President Trump said he expects to reach pricing deals with more drug companies following the Pfizer announcement. Photo: Win McNamee/Getty Images WASHINGTON—The Trump administration said it isn’t ...

This latest FDA program aims to provide speedier reviews for generic drugmakers who produce their products in the U.S. Keeping up its string of pilots in recent months, the FDA on Friday unwrapped a ...

The Food and Drug Administration on Tuesday quietly approved a generic form of mifepristone, one of the two medications used in most U.S. abortions. That makes the drug, from the company Evita ...

ANDERLECHT, Belgium--(BUSINESS WIRE)--A.forall is pleased to announce the acquisition of four FDA-approved injectable generics and two late-stage pipeline assets from Provepharm's US portfolio. With ...

NEW YORK, Sept 2 (Reuters) - Some Chinese companies now racing to make generic versions of Novo Nordisk's (NOVOb.CO), opens new tab Wegovy also supplied ingredients for more than a billion makeshift ...

Medications are rarely made from start to finish in a single country; raw materials, active ingredients and final products often cross multiple borders before reaching patients in the U.S., The New ...

Forbes contributors publish independent expert analyses and insights. Sally Pipes is a scholar and think tank CEO who writes on health care. America’s generic drug market is one of our greatest health ...

A new analysis from GoodRx explores how 2025 is shaping up for Food and Drug Administration drug approvals, and the early data tells a mixed story. Importantly, a growing disconnect remains between ...

In 2020, Novo Nordisk’s Canadian patent for semaglutide, the active ingredient in its blockbuster GLP-1 drugs Ozempic and Wegovy, quietly expired. The reason? A small missed maintenance fee, ...